Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

0(0%)

Results Posted

100%(4 trials)

Terminated

1(17%)

Phase Distribution

Ph phase_2

17%

Ph phase_4

33%

Ph phase_1

17%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

1(16.7%)

Phase 2Efficacy & side effects

1(16.7%)

Phase 3Large-scale testing

2(33.3%)

Phase 4Post-market surveillance

2(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(2)

Detailed Status

Completed4

Terminated1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (16.7%)

Phase 21 (16.7%)

Phase 32 (33.3%)

Phase 42 (33.3%)

Trials by Status

terminated117%

withdrawn117%

completed467%

Recent Activity

0 active trials

Showing 5 of 6

terminatedphase_1

Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia

NCT00140413

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT00803179Phase 1

Growth Hormone Therapy for Wasting in Cystic Fibrosis

Terminated

NCT00444964Phase 3

Growth Hormone Use in Adults With Prader-Willi Syndrome

Completed

NCT00256555Phase 2

Growth Hormone Treatment Study in Children With Cystic Fibrosis

Withdrawn

NCT00134420Phase 3

Growth Hormone and Chromosome 18q- and Abnormal Growth

Completed

NCT00140413Phase 4

Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia

Completed

NCT00212758Phase 4

A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6